Abrilumab Biosimilar - Research Grade

Human

ITGA4 + ITGB7

>1mg/ml

Human IgG2 Kappa

Etrolizumab Biosimilar - Research Grade (ICH5150)

https://www.imgt.org/mAb-DB/

ICH3002

P13612;P26010

Blue ice

ICH5139 is an unconjugated, non-therapeutic recombinant analog of abrilumab (AMG 181 / MEDI 7183), a fully human IgG2 kappa monoclonal antibody directed against the alpha4-beta7 integrin heterodimer. Built around the same target specificity as the originator drug, this research-grade biosimilar is intended solely for research use (RUO) and is not the clinical product. It gives investigators a reliable tool for studying alpha4-beta7-dependent leukocyte adhesion and gut-selective lymphocyte trafficking without sourcing scarce clinical material. Typical applications include use as a positive control or benchmark antibody in binding and neutralisation assays, in-vitro cell-adhesion and blocking studies, epitope and competition work, assay development and standardisation, and preclinical model characterisation. It is supplied unconjugated, low-endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg), and available in bulk milligram-to-gram quantities to support scale-up and reproducibility. Not for human or veterinary use. The molecular target is the alpha4-beta7 integrin, a heterodimer of integrin subunit alpha-4 (ITGA4, P13612) paired with integrin subunit beta-7 (ITGB7, P26010). Note that ITGA4 can also pair with beta-1 to form alpha4-beta1 (VLA-4); alpha4-beta7 specifically confers gut-selective homing. Expressed on subsets of memory T and B lymphocytes, alpha4-beta7 binds mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) on gut endothelial venules, and also fibronectin and VCAM-1. This interaction mediates the rolling, firm adhesion, and extravasation of leukocytes into gut-associated lymphoid tissue and intestinal mucosa. Because MAdCAM-1 expression is largely restricted to the gastrointestinal tract, selectively blocking alpha4-beta7 reduces immune-cell recruitment to the gut while sparing systemic and central-nervous-system trafficking, the basis of gut-selective anti-integrin strategies in inflammatory bowel disease research.

CD49 antigen-like family member D, Integrin alpha-IV, VLA-4 subunit alpha, Gut homing receptor beta subunit, Integrin alpha-4, Integrin beta-7, ITGA4, CD49D, ITGB7

Detects human ITGA4/ITGB7

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.